Sosei Group Corp

Overview

Sosei Group Corp (Sosei) is a biopharmaceutical company. The company develops and commercializes drugs. Its medical products include Ultibro, Seebri, Enerzair, Breezhaler, and Oravi. Its in house pipeline programs consists of Muscarinic M1 agonist, Muscarinic M4 agonist, SSTR agonist, Muscarinic M1 agonist (DLB), GLP-1 antagonist, H4 antagonist, EP4 antagonist, GLP-2 antagonist, GPR52 agonist, and PAR2 mAb. Sosei partnered pipeline program includes Adenosine A2a antagonist, GLP-1 agonist, CCR6 antagonist, MC4 antagonist, CGRP antagonist, GPR35 agonist, Pfizer collaboration, Genentech collaboration, Takeda collaboration, AbbVie collaboration, CXCR4 mAb, PAR2 Peptide, targeted GPCR degradation, AI augmented drug discovery, Ion Channels, mGlu5 NAM, and Orexin agonists. Its partners include AstraZeneca, AbbVie, Biohaven, Genentech, GSK, Takeda, and Pfizer. The company operates in Japan, and the UK. Sosei is headquartered in Chiyoda-ku, Tokyo, Japan.
Key Stats
Address
11F, PMO Hanzomon, 2-1, Koji-machi, CHIYODA-KU, Tokyo
Headquarters

Japan

Contact

81 3 52103290

No of Employees

190

Industry

Pharmaceuticals and Healthcare

Ticker Symbol & Exchange​

4565 [TYO]

Revenue (2020)

$83 m

-7.2% (2020 vs 2019)
Net Income (2020)

$14 m

6.3% (2020 vs 2019)
Net Profit Margin

17 %

13.7% (2020 vs 2019)
Market Cap *

$1,440 m

EPS *

$0.2

  *Note: Ratios based on the share price as of 8-September-2021, in absolute numbers and US$.

Peer Comparison

Key Parameters Sosei Group CorpChugai Pharmaceutical Co LtdSanten Pharmaceutical Co LtdTowa Pharmaceutical Co Ltd
Key Information
Headquarters Japan Japan Japan Japan
Headquarter City CHIYODA-KU CHUO-KU OSAKA-SHI KADOMA-SHI
Headquarter State/Province Tokyo Tokyo Osaka Osaka
No. of Employees 190 7,555 4,229 3,456
Entity Type Public Public Public Public

Products & Services

Sosei discovers and develops new medicines. The key products of the company include the following:

Products
  • Medicine:
  • Ultibro
  • Seebri
  • Vitae Eget Libero
  • Vitae Eget Libero
  • Vitae Eget Libero
  • Vitae Eget Libero
  • Vitae Eget Libero
  • Vitae Eget Libero
  • Vitae Eget Libero
Brands
  • Sosei Heptares
  • Ultibro
  • Seebri
  • Rutrum Elit
  • Rutrum Elit
  • Rutrum Elit
Key Financial Charts
Sales Growth
Operating Margin
Net Income Growth
EPS (Earnings per Share)
Debt to Equity Ratio
Return on Assets

Employees

Name Position Board Since Age Biography
Non Dignissim Eros Proin vel Convallis 2015 XX In vitae nisi ut tortor rutrum suscipit vel vitae ligula. Mauris sed tellus non augue ultricies ultricies. Aliquam vitae urna congue.
Non Dignissim Eros Proin vel Convallis 2015 XX In vitae nisi ut tortor rutrum suscipit vel vitae ligula. Mauris sed tellus non augue ultricies ultricies. Aliquam vitae urna congue.

History

Year Event Description
2021 Contracts/Agreements In July, the company entered into a collaboration with InveniAI LLC to identify new therapeutic…
2020 Contracts/Agreements In June, the company and AbbVie entered into a discovery alliance and option-to-license agreement to…
2019 Contracts/Agreements In July, the company signed a multi-target research collaboration and license agreement with Genentech to…
2019 Quis autem vel Ut enim ad minima veniam, quis nostrum exercitationem ullam corporis suscipit laboriosam
2018 Quis autem vel Ut enim ad minima veniam, quis nostrum exercitationem ullam corporis suscipit laboriosam
2017 Quis autem vel Ut enim ad minima veniam, quis nostrum exercitationem ullam corporis suscipit laboriosam

Locations


Sosei Co Ltd

Address

Kojimachi Tsuruya Hachiman Bldg. 5F, 2-4 Kojimachi, Chiyoda-ku
Japan

Telephone

81 3 52103290

Website

www.sosei.com
Sosei CVC Ltd

Address

Kojimachi Tsuruya Hachiman Building 5F, 2-4 Kojimachi, Chiyoda
Japan

Telephone

81 3 52103290

Website

www.sosei.com
Sosei R&D Ltd

Address

2nd Floor, London BioScience Innovation Centre, 2 Royal College Street, London
United Kingdom

Telephone

44 20 76912081

Heptares Therapeutics Ltd

Address

Steinmetz Building, Granta Park, Great Abington
United Kingdom

Telephone

44 1223 949100

Website

www.soseiheptares.com/about/corporate-details.html

Deals

Number of Deals
Deal Value (US$ m)

Latest Deals

Announced Date Headline Deal Type Acquirers / Investors / Surviving Entity Issuer / partner / Target
06 Jul 2021 Sosei Heptares and InveniAI Enter into Drug Discovery Collaboration Partnership InveniAI Corp; Sosei Group Corp
01 Feb 2021 Sosei Group (Sosei Heptares) Enters into Agreement with Metrion Biosciences Partnership Sosei Group Corp; Metrion Biosciences Ltd
12 Jan 2021 Sosei Group (Sosei Heptares) and PharmEnable Enter into Co-Development Agreement Partnership Sosei Group Corp; PharmEnable Ltd
22 Dec 2020 Lorem ipsum dolor sit amet, consectetur adipiscing elit Eiusmod Tempor Exercitation cillum velit
21 Dec 2020 Lorem ipsum dolor sit amet, consectetur adipiscing elit Eiusmod Tempor Exercitation cillum velit
01 Dec 2020 Lorem ipsum dolor sit amet, consectetur adipiscing elit Eiusmod Tempor Exercitation cillum velit

Jobs Overview

12

Active Jobs

1

Posted

2

Closed

Job Trends

Latest Jobs

Job title Company Country
Principal Scientist – Molecular Pharmacology Sosei Group Corp Japan
Immunologist Sosei Group Corp Japan
Cras Malesuada Dolor nisi Lorem minim amet cillum elit. Cursus Sed Pulvinar
Cras Malesuada Dolor nisi Lorem minim amet cillum elit. Cursus Sed Pulvinar
Cras Malesuada Dolor nisi Lorem minim amet cillum elit. Cursus Sed Pulvinar
Cras Malesuada Dolor nisi Lorem minim amet cillum elit. Cursus Sed Pulvinar